- Home
- ZDGE vs ARTV Comparison
ZDGE vs ARTV Comparison
Compare ZDGE & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- ARTV
- Stock Information
- Founded
- ZDGE 2008
- ARTV 2019
- Country
- ZDGE United States
- ARTV United States
- Employees
- ZDGE N/A
- ARTV N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- ARTV
- Sector
- ZDGE Technology
- ARTV
- Exchange
- ZDGE Nasdaq
- ARTV NYSE
- Market Cap
- ZDGE 40.3M
- ARTV 39.0M
- IPO Year
- ZDGE N/A
- ARTV 2024
- Fundamental
- Price
- ZDGE $3.81
- ARTV $2.04
- Analyst Decision
- ZDGE
- ARTV Strong Buy
- Analyst Count
- ZDGE 0
- ARTV 8
- Target Price
- ZDGE N/A
- ARTV $18.14
- AVG Volume (30 Days)
- ZDGE 419.5K
- ARTV 366.6K
- Earning Date
- ZDGE 06-12-2025
- ARTV 08-28-2025
- Dividend Yield
- ZDGE N/A
- ARTV N/A
- EPS Growth
- ZDGE N/A
- ARTV N/A
- EPS
- ZDGE N/A
- ARTV N/A
- Revenue
- ZDGE $29,511,000.00
- ARTV N/A
- Revenue This Year
- ZDGE N/A
- ARTV N/A
- Revenue Next Year
- ZDGE $1.07
- ARTV N/A
- P/E Ratio
- ZDGE N/A
- ARTV N/A
- Revenue Growth
- ZDGE 1.27
- ARTV N/A
- 52 Week Low
- ZDGE $1.73
- ARTV $1.47
- 52 Week High
- ZDGE $4.38
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- ZDGE 58.35
- ARTV N/A
- Support Level
- ZDGE $3.88
- ARTV N/A
- Resistance Level
- ZDGE $4.30
- ARTV N/A
- Average True Range (ATR)
- ZDGE 0.24
- ARTV 0.00
- MACD
- ZDGE -0.06
- ARTV 0.00
- Stochastic Oscillator
- ZDGE 18.05
- ARTV 0.00
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).